Walgreens Boots Alliance
Acquisitions
4
Major Deals Covered
$9.6B
Disclosed Deal Value
Walgreens Boots Alliance's largest disclosed acquisition here is VillageMD Investment for $5.2B in 2021. This page covers 4 major deals from 2014 to 2025, each with its price where disclosed and the reason behind it.
| Company | Year | Price | Purpose |
|---|---|---|---|
| Alliance Boots | 2014 | Undisclosed | Combine Walgreens with the European pharmacy, beauty and wholesale group Alliance Boots. |
| Rite Aid Stores | 2017 | $4.4B | Buy 1,932 Rite Aid stores and related assets after the full Rite Aid merger failed to win antitrust approval. |
| VillageMD Investment | 2021 | $5.2B | Take a majority stake in VillageMD to build primary-care clinics alongside stores. |
| Sycamore Partners Take-Private | 2025 | Undisclosed | Sycamore Partners acquired Walgreens Boots Alliance in a deal valued at about $10 billion in equity and up to $23.7 billion including debt and other obligations. |
2025
Sycamore Partners acquired Walgreens Boots Alliance in a deal valued at about $10 billion in equity and up to $23.7 billion including debt and other obligations.
WBA was delisted from Nasdaq; Walgreens, Boots, Shields Health Solutions, CareCentrix and VillageMD became separate private companies.
Completed August 28, 2025.
2021
$5.2B
Take a majority stake in VillageMD to build primary-care clinics alongside stores.
The strategy produced large impairments and was scaled back.
VillageMD now operates as a separate private company following the 2025 take-private.
2017
$4.4B
Buy 1,932 Rite Aid stores and related assets after the full Rite Aid merger failed to win antitrust approval.
Expanded the U.S. store base; many acquired locations were later converted or closed.
Completed in stages during 2017 and 2018.
2014
Combine Walgreens with the European pharmacy, beauty and wholesale group Alliance Boots.
Created Walgreens Boots Alliance, adding Boots UK, No7 and international wholesale operations.
Walgreens bought a 45% stake in 2012 and the remainder in 2014. Boots now operates separately from Walgreens under Sycamore ownership.
The current plan centers on core pharmacy execution, store productivity and cost control rather than the clinic-led diversification of the VillageMD years. That includes targeted store closures, a Houston distribution center closure and corporate layoffs announced in early 2026, alongside a small number of new store openings.
Walgreens makes most of its money dispensing prescriptions, paid largely by insurers and pharmacy benefit managers, with patient co-pays on top. Front-of-store retail (over-the-counter health, beauty, personal care, household goods and convenience items) adds traffic and margin, and pharmacy services such as immunizations and specialty pharmacy round out the mix. Prescription reimbursement rates are negotiated with PBMs and plans, so a large share of pharmacy economics sits outside the company's direct control. Since the take-private, Walgreens is a U.S.-focused operator; Boots and the former healthcare businesses are run as separate companies under Sycamore.
In April 2010, Walgreens acquired iconic New York City drugstore chain Duane Reade for $1.08 billion, instantly securing 257 high-density retail locations across Manhattan and the outer boroughs.
Walgreens acquired a 45% stake in Alliance Boots in August 2012 for $6.7 billion in cash and stock, exercising its option in December 2014 to acquire the remaining 55% for $15.3 billion to create Walgreens Boots Alliance.
Walgreens agreed to buy Rite Aid for $17.2 billion in 2015, but fierce FTC antitrust opposition forced the cancellation of the full buyout; instead, Walgreens bought 1,932 Rite Aid stores for $4.38 billion in 2017.
In October 2021, WBA invested $5.2 billion to increase its equity ownership in VillageMD from 30% to 63%, intending to open 1,000 doctor-staffed primary care clinics attached to Walgreens stores.
Walgreens acquired full ownership of specialty pharmacy integrator Shields Health Solutions between 2021 and 2022 for approximately $2.3 billion, partnering with hospital networks to manage complex drug dispensing.
Between 2021 and 2023, WBA acquired 100% of CareCentrix for approximately $722 million, expanding into home-based health monitoring and post-hospital discharge care coordination.
Slower-than-expected patient volume, unprofitable clinic expansion in rural markets, and shifting payer models caused massive operational losses, forcing a $5.8 billion impairment write-down in early 2024.
Sycamore Partners completed an all-cash take-private buyout of Walgreens Boots Alliance on August 28, 2025, delisting WBA from Nasdaq and carving out the group's subsidiaries into independent companies.
Sycamore separated Boots UK into an independent, standalone British retail pharmacy business with its own balance sheet and governance, ending the joint corporate parent structure established in 2014.
Walgreens sold down its multi-billion-dollar equity stake in Cencora in public offerings to raise liquidity while maintaining a long-term commercial pharmaceutical distribution agreement.
Acquiring clinic operators and post-acute providers failed to generate promised retail pharmacy cross-traffic, saddling the company with heavy debt and distracting from core neighborhood pharmacy operations.
Under Sycamore Partners, Walgreens is avoiding large debt-fueled corporate buyouts, focusing instead on bolt-on pharmacy script acquisitions from closing independent and regional drugstores.
Compare corporate acquisition records, deal values, and strategic targets
Explore Walgreens Boots Alliance
Core profile pages, founders and related research hubs for this company.